# Hematocrit Test Market > Hematocrit Test Market Research Report Information By Product (Analyzer, Hematocrit Test Meter), Indication (Anemia, Leukemia, Lymphoma, Congenital Heart Disease, Kidney Tumor), End-User (Hospital, Clinic, Diagnostic Center) – Global Forecast Till 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 7.67% - **2024:** $ 2.66 Billion - **2025:** $ 2.86 Billion - **2035:** $ 6 Billion - **Key Players:** Abbott Laboratories (US), Roche Diagnostics (CH), Siemens Healthineers (DE), Thermo Fisher Scientific(US), Becton Dickinson and Company (US), Ortho Clinical Diagnostics (US), Sysmex Corporation (JP), Mindray Medical International Limited (CN), HemoCue AB (SE) **Report ID:** MRFR/LS/4105-HCR · **Pages:** 110 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/hematocrit-test-market-5553 --- ## Market Summary ## **Hematocrit Test Market Overview** The hematocrit test market Size valued at USD 2.47 Billion in 2023. The hematocrit test market industry is projected to rise from USD 2.57 Billion in 2024 to USD 4.56 Billion by 2032, exhibiting a compound yearly growth rate (CAGR) of 8.3% during the forecast period (2024 - 2032). Also known as packed-cell volume (PCV) test, hematocrit test is used to measure the percentage of Red Blood Cells (RBCs) in the blood. The major function of the RBCs is to carry blood throughout the body. The test is usually performed to diagnose various diseases such as anemia, leukemia, lymphoma, congenital heart disease, and others. The test determines the elevation in the percentage of normal RBCs which is 38.8%-50% in men and 34.9%-44.5% in women. The hematocrit test is one of the tests included under complete blood count (CBC) test. ## **Hematocrit Test Market Trends** Cardiovascular diseases, cancer, and kidney diseases are increasing the economic burden of various developing and developed nations across the globe. The hematocrit test market is driven by rising prevalence of chronic diseases such as cardiovascular diseases, diabetes, and others along with changing lifestyle, and increasing demand for diagnostic devices for cardiovascular diseases. However, limited number of trained personnel has restrained the growth of the hematocrit test market. However, the high cost of diagnosis and treatment of cardiovascular diseases also restrains the growth of the market. As per the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the overall prevalence of Chronic Kidney Disease (CKD) in the general population across the globe is nearly 14%. However, the growth of the hematocrit test market is restrained by the inaccurate or misleading result of the test and unawareness about hematocrit test in the diagnosis of the disease. ## **Hematocrit Test Market Segmentation** The hematocrit test market is segmented on the basis of product, indication, devices, and end-user. ### **Hematocrit Test Product Insights** On the basis of product, the hematocrit test market is segmented into the analyzer, hematocrit test meter, and others. ### **Hematocrit Test Indication Insights** On the basis of indication, the hematocrit test market is segmented into anemia, [leukemia](../../../reports/leukemia-therapeutics-market-7425), lymphoma, congenital heart disease, kidney tumor, and others. ### **Hematocrit Test End-user Insights** On the basis of the end-user, the hematocrit test market is segmented into hospitals & clinics, diagnostic centers, and others. ## **Hematocrit Test Regional Analysis**       The hematocrit test market consists of four major regions namely, the Americas, Europe, Asia Pacific and the Middle East & Africa, with the Americas capturing the largest market share. The growth of the market is attributed to an increase in the demand for diagnostic procedures, and rising importance of hematology testing for the diagnosis of various chronic diseases.  North America accounts for the major share in the American hematocrit test market which is attributed to extensive use of hematocrit test with other diagnostic tests. According to the Center for the Disease Control and Prevention (CDC), as of 2012, nearly half of all the adults, 117 million population in the U.S. had one or more chronic health conditions. One in four adults were diagnosed with two or more chronic health diseases. In Europe, the growth of the market is driven by increasing demand for diagnostic devices and instrument in hospitals and diagnostic centers. Germany, the U.K, and France are the major contributors to the growth of the market owing to an increase in the number of key players engaged in the manufacturing of medical devices and instruments and rising expenditure in research and development by these major economies. Additionally, well-developed healthcare sector, ever-increasing patient population and high healthcare expenditure by the European nations fuel the market growth. The Asia Pacific is expecting the fastest growth in the market due to the flourishing growth of healthcare industries in developing economies such as India. Additionally, the ever-increasing prevalence of kidney diseases and cardiovascular diseases and rising demand for quality devices in the healthcare sector is expected to lead the use of advanced equipment, which, in turn, may speed up the market growth in the region. Rising geriatric population with chronic diseases further creates the economic burden on the developing nations thereby accelerating the market growth. The Middle East & Africa hold the least share in the market. The market in this regions exhibits steady growth owing to an increase in the demand for the diagnostic and treatment services.  In the Middle East and Africa, the United Arab Emirates (UAE) hold the largest market share owing to the availability of diagnostic and treatment services. Africa shows slow growth due to low technology penetration in developing countries. ## **Key Players in the Hematocrit Test Market ** Some of the key players in hematocrit test market are  **Intended Audience** ## Market Drivers ### Rising Geriatric Population The Hematocrit Test Market is significantly influenced by the rising geriatric population, which is more susceptible to various health conditions, including anemia and cardiovascular diseases. As individuals age, the likelihood of developing these conditions increases, leading to a higher demand for regular hematocrit testing. According to demographic data, the global population aged 65 and older is projected to reach 1.5 billion by 2050. This demographic shift necessitates enhanced healthcare services, including routine blood tests to monitor hematocrit levels. Consequently, the Hematocrit Test Market is likely to see substantial growth as healthcare providers adapt to the needs of an aging population. ### Emphasis on Preventive Healthcare Measures The growing emphasis on preventive healthcare measures is shaping the Hematocrit Test Market. Healthcare providers are increasingly advocating for routine blood tests, including hematocrit testing, as part of comprehensive health assessments. This proactive approach aims to identify potential health issues before they escalate, thereby improving patient outcomes. Data indicates that preventive healthcare can reduce overall healthcare costs by up to 30% by minimizing the need for more extensive treatments. As awareness of the benefits of preventive care continues to rise, the demand for hematocrit testing is likely to increase, further propelling the Hematocrit Test Market. ### Technological Innovations in Hematocrit Testing The Hematocrit Test Market is experiencing a surge in technological innovations that enhance the accuracy and efficiency of hematocrit testing. Advanced devices, such as automated analyzers and portable testing kits, are being developed, which streamline the testing process and reduce human error. These innovations not only improve patient outcomes but also increase the throughput of laboratories. According to recent data, the adoption of automated hematology analyzers has led to a 30% increase in testing efficiency in clinical settings. As healthcare providers seek to optimize their operations, the demand for these advanced technologies is likely to grow, driving the Hematocrit Test Market forward. ### Increased Investment in Healthcare Infrastructure Investment in healthcare infrastructure is a pivotal factor driving the Hematocrit Test Market. Governments and private entities are increasingly allocating resources to enhance laboratory capabilities and expand access to diagnostic testing. This trend is particularly evident in emerging economies, where healthcare systems are being modernized to meet growing demands. Enhanced laboratory infrastructure facilitates the implementation of advanced hematocrit testing technologies, thereby improving diagnostic accuracy and patient care. As healthcare investments continue to rise, the Hematocrit Test Market is expected to benefit from improved access to testing services and increased adoption of innovative testing solutions. ### Growing Prevalence of Anemia and Related Disorders The rising prevalence of anemia and related blood disorders is a critical driver for the Hematocrit Test Market. Anemia affects millions worldwide, with estimates suggesting that approximately 1.62 billion people are anemic, particularly in developing regions. This increasing incidence necessitates regular monitoring of hematocrit levels, thereby propelling the demand for hematocrit testing. Healthcare systems are increasingly prioritizing early diagnosis and management of anemia, which further emphasizes the importance of hematocrit tests. As awareness of anemia's health implications grows, the Hematocrit Test Market is poised for expansion, catering to the needs of healthcare providers and patients alike. ## Future Outlook The Hematocrit Test Market is projected to grow at a 7.67% CAGR from 2025 to 2035, driven by technological advancements, increasing prevalence of blood disorders, and rising demand for point-of-care testing. **New opportunities:** - Development of portable hematocrit testing devices for remote diagnostics. Integration of AI analytics in hematocrit testing for enhanced accuracy. Expansion of telehealth services incorporating hematocrit monitoring solutions. By 2035, the Hematocrit Test Market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Product: Analyzer (Largest) vs. Hematocrit Test Meter (Fastest-Growing) In the Hematocrit Test Market, the product segment is predominantly led by analyzers, holding the largest market share. This segment benefits from advanced technology and precision, which are critical for hematocrit testing. In contrast, hematocrit test meters are rapidly gaining traction, thanks to their user-friendly design and portability, making them an essential tool in both clinical and home settings. Analyzer (Dominant) vs. Hematocrit Test Meter (Emerging) Analyzers in the Hematocrit Test Market are recognized for their accuracy and efficiency, making them the dominant choice among healthcare professionals. They facilitate high-throughput testing, essential in laboratory environments. Conversely, hematocrit test meters are carving out their niche as an emerging solution due to their convenience and ease of use, appealing particularly to outpatient settings and home care. This shift towards more accessible testing methods indicates a growing demand for portable solutions in the market. As technology continues to enhance their capabilities, these meters are expected to see significant growth. ### By Indication: Anemia (Largest) vs. Leukemia (Fastest-Growing) The Hematocrit Test Market is primarily dominated by the indication of anemia, which holds the largest share among various conditions. This is largely due to the rising prevalence of anemia across diverse populations, driven by factors such as nutritional deficiencies and chronic diseases. Following anemia, leukemia stands out as a rapidly emerging segment, reflecting a significant shift in healthcare focus towards cancer diagnosis and monitoring. This segment is witnessing increased demand due to heightened awareness and advancements in diagnostic technologies. Anemia: Dominant vs. Leukemia: Emerging Anemia is recognized as the dominant indication in the Hematocrit Test Market, attributable to widespread occurrences linked to various socio-economic factors and health conditions. This segment benefits from robust screening programs and awareness campaigns aimed at early detection and timely treatment. On the other hand, leukemia represents an emerging segment, marked by a surge in research and development efforts aimed at improving diagnostic capabilities. With the rising incidence of blood cancers, healthcare providers are increasingly employing hematocrit testing as a critical component in the diagnostic pathway for leukemia, thus fostering growth and innovation in this area. ### By End-user: Hospitals & Clinics (Largest) vs. Diagnostic Centers (Fastest-Growing) The Hematocrit Test Market is primarily dominated by the 'hospitals & clinics' segment, accounting for a significant proportion of market share. Hospitals and clinics benefit from a steady influx of patients requiring hematological tests, solidifying their position as the largest end-user segment. Conversely, 'diagnostic centers' are gaining a notable presence within the market. Their increasing adoption is fueled by the rising demand for quick and accurate diagnostic solutions, positioning them as a crucial player in this landscape. In terms of growth trends, diagnostic centers are emerging as the fastest-growing segment due to advancements in technology and an increase in preventive healthcare measures. The shift towards outpatient care has also propelled the growth of diagnostic centers, as they offer specialized tests with faster turnaround times. With the continuous evolution of healthcare protocols, these centers are expected to expand their offerings further, enhancing their market penetration in the coming years. Hospitals & Clinics (Dominant) vs. Diagnostic Centers (Emerging) The 'hospitals & clinics' segment is characterized by its comprehensive approach to patient care, where hematocrit tests are crucial for the diagnosis and monitoring of various health conditions. These facilities have the infrastructure and personnel needed to offer a wide range of hematological services, making them the dominant choice for patients. In contrast, 'diagnostic centers' represent an emerging segment focused on streamlining the testing process through specialized services. They are equipped with advanced technology that allows for quick and efficient testing, catering to a growing population that seeks immediate results. This agility and specialization give diagnostic centers a competitive edge, highlighting their potential for rapid growth in the Hematocrit Test Market. ## Regional Market Share Analysis ### North America : Market Leader in Innovation North America is the largest market for hematocrit tests, holding approximately 45% of the global market share. The region's growth is driven by advanced healthcare infrastructure, increasing prevalence of chronic diseases, and a strong emphasis on early diagnosis. Regulatory support from agencies like the FDA further catalyzes market expansion, ensuring the availability of innovative testing solutions. The United States is the primary contributor, with significant investments in research and development. Key players such as Abbott Laboratories and Thermo Fisher Scientific dominate the landscape, leveraging cutting-edge technology to enhance testing accuracy and efficiency. The competitive environment is characterized by strategic partnerships and collaborations aimed at improving patient outcomes. ### Europe : Regulatory Framework Enhancements Europe is the second-largest market for hematocrit tests, accounting for around 30% of the global share. The region benefits from stringent regulatory frameworks that ensure high-quality testing standards. The European Medicines Agency (EMA) plays a crucial role in facilitating market access for innovative hematology products, driving demand for advanced testing solutions. Leading countries include Germany, France, and the UK, where healthcare investments are robust. Major players like Roche Diagnostics and Siemens Healthineers are actively involved in product development and market expansion. The competitive landscape is marked by a focus on technological advancements and collaborations with healthcare providers to enhance diagnostic capabilities. ### Asia-Pacific : Emerging Market Potential Asia-Pacific is witnessing significant growth in the hematocrit test market, driven by increasing healthcare expenditures and rising awareness of chronic diseases. The region holds approximately 20% of the global market share, with countries like China and India leading the charge. Government initiatives aimed at improving healthcare access and quality are pivotal in driving demand for hematocrit testing solutions. China is the largest market in the region, supported by a growing population and expanding healthcare infrastructure. Key players such as Sysmex Corporation and Mindray Medical International are focusing on innovation and affordability to capture market share. The competitive landscape is evolving, with local manufacturers emerging alongside established global players, enhancing the overall market dynamics. ### Middle East and Africa : Untapped Market Opportunities The Middle East and Africa region is gradually emerging in the hematocrit test market, holding about 5% of the global share. Growth is primarily driven by increasing investments in healthcare infrastructure and rising awareness of diagnostic testing. Governments are prioritizing healthcare reforms, which are expected to enhance access to hematocrit testing in underserved areas. Countries like South Africa and the UAE are leading the market, with a focus on improving healthcare services. The competitive landscape includes both international players and local manufacturers, with companies like Becton Dickinson and Ortho Clinical Diagnostics making significant inroads. The region presents untapped opportunities for growth, particularly in rural and remote areas where healthcare access is limited. ## Competitive Benchmarking The Hematocrit Test Market is characterized by a dynamic competitive landscape, driven by advancements in technology, increasing demand for diagnostic testing, and a growing emphasis on personalized medicine. Key players such as Abbott Laboratories (US), Roche Diagnostics (CH), and Siemens Healthineers (DE) are at the forefront, each adopting distinct strategies to enhance their market presence. Abbott Laboratories (US) focuses on innovation, particularly in point-of-care testing solutions, which aligns with the rising trend of decentralized healthcare. Meanwhile, Roche Diagnostics (CH) emphasizes partnerships and collaborations to expand its product offerings and enhance its diagnostic capabilities. Siemens Healthineers (DE) is investing heavily in digital transformation, integrating AI and data analytics into its hematology solutions, thereby improving efficiency and accuracy in testing. The competitive structure of the Hematocrit Test Market appears moderately fragmented, with several players vying for market share. Companies are increasingly localizing manufacturing and optimizing supply chains to enhance operational efficiency and reduce costs. This trend is particularly evident as firms seek to mitigate risks associated with global supply chain disruptions. The collective influence of these key players shapes a competitive environment where innovation and operational excellence are paramount. In August 2025, Abbott Laboratories (US) announced the launch of a new portable hematocrit testing device designed for use in remote and resource-limited settings. This strategic move not only expands Abbott's product portfolio but also addresses the growing need for accessible healthcare solutions in underserved regions. The introduction of this device is likely to enhance Abbott's competitive edge by catering to a broader demographic, thereby increasing its market penetration. In September 2025, Roche Diagnostics (CH) entered into a strategic partnership with a leading telehealth provider to integrate its hematocrit testing solutions into [remote patient monitoring](https://www.marketresearchfuture.com/reports/remote-patient-monitoring-market-10905) systems. This collaboration is significant as it aligns with the ongoing shift towards telemedicine, allowing for more efficient patient management and timely diagnostics. By leveraging telehealth platforms, Roche is poised to enhance its service delivery and expand its reach in the market. In October 2025, Siemens Healthineers (DE) unveiled a new AI-driven analytics platform aimed at optimizing hematology workflows in clinical laboratories. This innovation is indicative of Siemens' commitment to digital transformation and reflects a broader trend in the industry towards the integration of advanced technologies. The platform is expected to streamline operations, reduce turnaround times, and improve diagnostic accuracy, thereby reinforcing Siemens' position as a leader in the hematology space. As of October 2025, the Hematocrit Test Market is witnessing trends that emphasize digitalization, sustainability, and the integration of artificial intelligence. Strategic alliances are increasingly shaping the competitive landscape, enabling companies to leverage complementary strengths and enhance their service offerings. Looking ahead, it is anticipated that competitive differentiation will evolve, with a pronounced shift from price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This evolution underscores the necessity for companies to adapt and innovate continuously to maintain a competitive edge in a rapidly changing market. ## Report Scope | MARKET SIZE 2024 | 2.659(USD Billion) | | --- | --- | | MARKET SIZE 2025 | 2.863(USD Billion) | | MARKET SIZE 2035 | 5.996(USD Billion) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.67% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Billion | | Key Companies Profiled | Abbott Laboratories (US), Roche Diagnostics (CH), Siemens Healthineers (DE), Thermo Fisher Scientific (US), Becton Dickinson and Company (US), Ortho Clinical Diagnostics (US), Sysmex Corporation (JP), Mindray Medical International Limited (CN), HemoCue AB (SE) | | Segments Covered | Product | | Key Market Opportunities | Integration of advanced diagnostic technologies enhances accuracy in the Hematocrit Test Market. | | Key Market Dynamics | Rising demand for rapid diagnostic tools drives innovation and competition in the Hematocrit Test Market. | | Countries Covered | North America, Europe, APAC, South America, MEA | ## Frequently Asked Questions **Q: What is the projected market valuation of the Hematocrit Test Market by 2035?** A: The Hematocrit Test Market is projected to reach a valuation of 5.996 USD Billion by 2035. **Q: What was the market valuation of the Hematocrit Test Market in 2024?** A: In 2024, the Hematocrit Test Market was valued at 2.659 USD Billion. **Q: What is the expected CAGR for the Hematocrit Test Market during the forecast period 2025 - 2035?** A: The expected CAGR for the Hematocrit Test Market during the forecast period 2025 - 2035 is 7.67%. **Q: Which companies are considered key players in the Hematocrit Test Market?** A: Key players in the Hematocrit Test Market include Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, and Thermo Fisher Scientific. **Q: What are the main product segments in the Hematocrit Test Market?** A: The main product segments in the Hematocrit Test Market include analyzers, hematocrit test meters, and others. **Q: What is the projected market size for hematocrit test meters by 2035?** A: The market size for hematocrit test meters is projected to reach 2.4875 USD Billion by 2035. **Q: How does the market for anemia-related hematocrit tests compare to leukemia-related tests?** A: The market for anemia-related hematocrit tests is projected to reach 1.8 USD Billion, whereas leukemia-related tests are expected to reach 1.2 USD Billion by 2035. **Q: What is the expected growth in the hospitals and clinics segment of the Hematocrit Test Market?** A: The hospitals and clinics segment is expected to grow to 3.0 USD Billion by 2035. **Q: What is the projected market size for diagnostic centers in the Hematocrit Test Market?** A: The market size for diagnostic centers is projected to reach 1.8 USD Billion by 2035. **Q: What indications are driving the growth of the Hematocrit Test Market?** A: Indications driving growth include anemia, leukemia, lymphoma, and congenital heart disease, among others. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/hematocrit-test-market-5553*